Lite Strategy

Lite Strategy EBIT Growth

The Year-over-Year EBIT Growth of Lite Strategy (LITS) as of Nov 20, 2026 is 29.71 %. In the previous year, Year-over-Year EBIT Growth was -220.03 % — a change of -113.50% (higher).

EBIT Growth

29.71 %

YoY

-113.50%

Last updated:

Year-over-Year EBIT Growth of Lite Strategy is 2026 29.71 % . Year-over-Year EBIT Growth of Lite Strategy was 2025 -220.03 % . It decreases by -113.50% higher compared to the previous year.

The Lite Strategy EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-61.77 USD
Jan 1, 2020
44.43 USD
Jan 1, 2021
-135.11 USD
Jan 1, 2022
-24.92 USD
Jan 1, 2023
51.30 USD
Jan 1, 2024
139.55 USD
Jan 1, 2025
-220.03 USD
Jan 1, 2026
29.71 USD
The Lite Strategy EBIT Growth history
YEAREBIT GrowthYoY
29.71 %-113.50%
-220.03 %-257.67%
139.55 %+172.06%
51.30 %-305.81%
-24.92 %-81.55%
-135.11 %-404.09%
44.43 %-171.93%
-61.77 %-95.25%
-1,301.26 %-1,268.80%
111.33 %+209.97%
35.92 %-276.54%
-20.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Year-over-Year EBIT Growth of Lite Strategy is 29.71 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Lite Strategy

All Key Metrics — Lite Strategy